• Convertible noteholders agree to maturity date extension
• Additional $1.25M unsecured loan secured
• Funding to provide ongoing working capital

Noxopharm Limited (ASX:NOX) has announced that its existing convertible noteholders have approved the extension of the maturity date of their convertible notes to 2 January 2027, subject to shareholder approval. This will allow the company to access rebate funds of approximately $2,800,000 from the Australian Federal Government's Research and Development Tax Incentive Scheme for the financial year ended 30 June 2025, providing additional ongoing working capital. The noteholders will be paid accrued interest of $327,000 in aggregate on the convertible notes in cash for the period ending 2 January 2026, with the interest accruing from 2 January 2026 capitalised daily until maturity. As an incentive, the noteholders will be granted 520,000 additional unlisted options. Additionally, the company has entered into an unsecured loan agreement with 4F Investments Pty Limited, an entity owned and controlled by Noxopharm Chairman Mr Fred Bart, for a $1,250,000 loan at 12% p.a. interest. The funds from the loan will be used for Noxopharm's ongoing working capital requirements, and the intention is for this loan to be rolled into a convertible note if approved by shareholders at the upcoming AGM.